Table 2.
HRs Per 1‐SD (2.4) Increase of CERT2 for Different End Points and C‐Indices for Models With and Without CERT2
| End Point | HR (95% CI) | C‐Statistic −CERT2 | C‐Statistic +CERT2 | P Value |
|---|---|---|---|---|
| MACE or HHF | ||||
| Model 0 | 1.32 (1.26–1.39) | 0.510 (0.498–0.522) | 0.579 (0.565–0.594) | <0.0001 |
| Model 1 | 1.35 (1.28–1.42) | 0.665 (0.651–0.678) | 0.684 (0.671–0.697) | <0.0001 |
| Model 2 | 1.26 (1.20–1.33) | 0.693 (0.680–0.706) | 0.701 (0.688–0.715) | <0.0001 |
| Model 3 | 1.08 (1.02–1.15) | 0.750 (0.737–0.763) | 0.751 (0.738–0.764) | 0.009 |
| MACE | ||||
| Model 0 | 1.30 (1.24–1.37) | 0.508 (0.495–0.521) | 0.575 (0.559–0.590) | <0.0001 |
| Model 1 | 1.32 (1.25–1.39) | 0.654 (0.640–0.669) | 0.672 (0.658–0.686) | <0.0001 |
| Model 2 | 1.23 (1.16–1.31) | 0.682 (0.667–0.696) | 0.689 (0.675–0.704) | <0.0001 |
| Model 3 | 1.08 (1.02–1.15) | 0.731 (0.717–0.745) | 0.732 (0.718–0.746) | 0.012 |
| Major coronary event | ||||
| Model 0 | 1.26 (1.19–1.33) | 0.515 (0.502–0.529) | 0.566 (0.550–0.582) | <0.0001 |
| Model 1 | 1.28 (1.21–1.36) | 0.642 (0.627–0.657) | 0.656 (0.641–0.671) | <0.0001 |
| Model 2 | 1.20 (1.13–1.27) | 0.671 (0.656–0.687) | 0.676 (0.661–0.692) | <0.0001 |
| Model 3 | 1.07 (1.00–1.14) | 0.717 (0.702–0.732) | 0.717 (0.702–0.732) | 0.053 |
| Cardiovascular death | ||||
| Model 0 | 1.57 (1.45–1.69) | 0.510 (0.490–0.529) | 0.625 (0.602–0.648) | <0.0001 |
| Model 1 | 1.47 (1.35–1.59) | 0.729 (0.710–0.749) | 0.752 (0.733–0.770) | <0.0001 |
| Model 2 | 1.38 (1.26–1.50) | 0.760 (0.741–0.779) | 0.771 (0.752–0.789) | <0.0001 |
| Model 3 | 1.14 (1.04–1.26) | 0.831 (0.815–0.847) | 0.831 (0.815–0.847) | 0.005 |
| MI | ||||
| Model 0 | 1.16 (1.08–1.25) | 0.512 (0.493–0.531) | 0.542 (0.521–0.564) | 0.0001 |
| Model 1 | 1.23 (1.14–1.33) | 0.649 (0.628–0.670) | 0.657 (0.636–0.678) | <0.0001 |
| Model 2 | 1.15 (1.06–1.25) | 0.675 (0.655–0.696) | 0.680 (0.659–0.700) | 0.0009 |
| Model 3 | 1.06 (0.97–1.16) | 0.707 (0.687–0.728) | 0.708 (0.688–0.729) | 0.176 |
| HHF | ||||
| Model 0 | 1.52 (1.35–1.70) | 0.523 (0.495–0.551) | 0.619 (0.587–0.652) | <0.0001 |
| Model 1 | 1.56 (1.39–1.76) | 0.761 (0.736–0.787) | 0.787 (0.763–0.811) | <0.0001 |
| Model 2 | 1.45 (1.28–1.64) | 0.800 (0.777–0.822) | 0.811 (0.789–0.833) | <0.0001 |
| Model 3 | 1.02 (0.89–1.17) | 0.892 (0.875–0.909) | 0.892 (0.875–0.909) | 0.763 |
| Stroke | ||||
| Model 0 | 1.29 (1.15–1.46) | 0.499 (0.470–0.529) | 0.575 (0.541–0.610) | <0.0001 |
| Model 1 | 1.32 (1.16–1.49) | 0.655 (0.623–0.687) | 0.672 (0.640–0.703) | <0.0001 |
| Model 2 | 1.29 (1.14–1.48) | 0.678 (0.644–0.711) | 0.687 (0.655–0.720) | 0.0001 |
| Model 3 | 1.15 (0.99–1.33) | 0.719 (0.689–0.750) | 0.722 (0.692–0.752) | 0.059 |
| All‐cause death | ||||
| Model 0 | 1.54 (1.45–1.64) | 0.502 (0.486–0.518) | 0.624 (0.605–0.643) | <0.0001 |
| Model 1 | 1.44 (1.35–1.54) | 0.711 (0.695–0.727) | 0.736 (0.721–0.752) | <0.0001 |
| Model 2 | 1.34 (1.25–1.44) | 0.743 (0.727–0.758) | 0.754 (0.738–0.770) | <0.0001 |
| Model 3 | 1.12 (1.04–1.21) | 0.800 (0.785–0.815) | 0.801 (0.786–0.815) | 0.003 |
Model 0 includes the Cardiovascular Event Risk Test (CERT2) score and randomized treatment. Model 1 includes CERT2 score, randomized treatment, age, sex, prior myocardial infarction (MI), coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), multivessel coronary artery disease), diabetes mellitus, hypertension, history of smoking, polyvascular disease, geographic region, systolic blood pressure, and body mass index. Model 2 includes the following covariates in addition to model 1: hemoglobin, white blood cell count, Chronic Kidney Disease Epidemiology Collaboration, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and triglycerides. Model 3 includes the following covariates in addition to model 2: high‐sensitivity troponin T, pro‐B‐type natriuretic peptide, cystatin C, high‐sensitivity C‐reactive protein, and interleukin 6. P value relates to the significance of the hazard ratio (HR). HHF indicates hospitalization for heart failure; and MACE, major adverse cardiovascular event.